{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
ATAI Life Sciences NV
ATAI Life Sciences NV Sees Revision in Stock Evaluation Amid Mixed Performance Indicators
ATAI Life Sciences NV, a small-cap in the Pharmaceuticals and Biotechnology sector, has seen mixed technical indicators amid fluctuating stock performance. The company has experienced a significant annual increase, outperforming the S&P 500, but shows a year-to-date decline. Current trading reflects a range between $3.45 and $3.64.
ATAI Life Sciences Forms Death Cross, Signaling Potential Bearish Trend
ATAI Life Sciences NV has encountered a technical event known as a Death Cross, indicating potential market sentiment shifts. The stock has seen a recent decline, contributing to a negative year-to-date performance, despite a strong annual gain. Mixed technical indicators suggest possible volatility ahead for the company.
ATAI Life Sciences Hits Day Low of $3.53 Amid Price Pressure
ATAI Life Sciences NV saw a notable decline in its stock price amid a challenging trading session. Despite a strong annual performance, the company faces financial challenges, including a low return on equity and a high price-to-book ratio, indicating potential risks in its market position.
ATAI Life Sciences Opens Weak with 10% Gap Down Amid Market Concerns
ATAI Life Sciences NV, a small-cap pharmaceutical company, opened with a notable loss today, continuing a downward trend over the past month. The company has a market capitalization of around USD 1.41 billion, negative return on equity, and a unique financial structure characterized by a negative debt-to-equity ratio.
ATAI Life Sciences Hits Day High with 12.63% Surge in Stock Price
ATAI Life Sciences NV has seen notable stock activity, achieving a significant intraday high and strong short-term gains. Over the past year, the company has outperformed the S&P 500, with impressive long-term returns. However, it faces challenges, including a negative return on equity and a small market capitalization.
Is ATAI Life Sciences NV technically bullish or bearish?
As of October 10, 2025, ATAI Life Sciences NV shows a mildly bullish trend with positive momentum from MACD and Bollinger Bands, despite bearish RSI signals, and has significantly outperformed the S&P 500 year-to-date with a return of 306.02%.
Is ATAI Life Sciences NV technically bullish or bearish?
As of October 10, 2025, ATAI Life Sciences NV shows a mildly bullish trend with strong performance, having returned 283.46% year-to-date compared to the S&P 500's 11.41%, despite some bearish signals in RSI and Dow Theory.
Is ATAI Life Sciences NV technically bullish or bearish?
As of October 10, 2025, ATAI Life Sciences NV shows a mildly bullish trend with strong performance, having returned 283.46% year-to-date, despite some bearish signals from the RSI and Dow Theory.
ATAI Life Sciences NV Hits New 52-Week High of $5.96
ATAI Life Sciences NV achieved a new 52-week high of USD 5.96 on September 24, 2025, reflecting a significant year-over-year gain. The company, with a market capitalization of USD 969 million, remains unprofitable and has a high price-to-book ratio, indicating a premium valuation.
ATAI Life Sciences NV Hits New 52-Week High of $5.76
ATAI Life Sciences NV achieved a new 52-week high of USD 5.76 on September 23, 2025, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 969 million, the company operates in the competitive Pharmaceuticals & Biotechnology sector, focusing on growth despite financial challenges.
ATAI Life Sciences Hits Day High with 14.96% Surge in Stock Price
ATAI Life Sciences NV has seen significant stock activity, with notable gains over various time frames, including a remarkable increase over the past month. However, the company faces challenges, including a negative return on equity and ongoing losses, as it operates in a competitive Pharmaceuticals & Biotechnology sector.
Is ATAI Life Sciences NV technically bullish or bearish?
As of September 11, 2025, ATAI Life Sciences NV shows a bullish trend supported by strong daily moving averages and weekly KST, despite some bearish momentum in weekly and monthly RSI readings, and has significantly outperformed the S&P 500 with year-to-date and one-year returns of 254.89% and 280.65%, respectively.
Is ATAI Life Sciences NV overvalued or undervalued?
As of May 14, 2025, ATAI Life Sciences NV is considered risky due to overvaluation indicated by a price-to-book ratio of 3.18, an EV to EBITDA of -4.41, and a negative ROCE of -130.41%, despite a strong year-to-date stock performance of 254.89%.
Is ATAI Life Sciences NV overvalued or undervalued?
As of May 14, 2025, ATAI Life Sciences NV is considered risky and overvalued due to significant negative financial metrics, including a P/E ratio that is not applicable, a Price to Book Value of 3.18, an EV to Sales ratio of 215.20, and poor returns on capital and equity, despite a year-to-date return of 51.88%.
Is ATAI Life Sciences NV technically bullish or bearish?
As of May 28, 2025, the technical trend is bullish with strong daily moving averages and a bullish weekly MACD, though caution is advised due to a bearish monthly KST and mixed signals from longer-term indicators.
What does ATAI Life Sciences NV do?
ATAI Life Sciences NV is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $2 million and a net loss of $26 million as of March 2025, with a market cap of $445.67 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -63.76%.
How big is ATAI Life Sciences NV?
As of Jun 18, ATAI Life Sciences NV has a market capitalization of 445.67 million, with net sales of 1.87 million and a net profit of -137.53 million over the latest four quarters. The company reported shareholder's funds of 116.30 million and total assets of 159.39 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
